Teitel J M, Rosenberg R D
J Clin Invest. 1983 May;71(5):1383-91. doi: 10.1172/jci110891.
We have studied the accessibility of Factor Xa to neutralization by the heparin-antithrombin complex within plasma and whole blood. This serine protease was detected by measuring the concentrations of activation fragments (F2/F1+2) cleaved from prothrombin. The levels of F2/F1+2) were quantitated by means of a sensitive and specific radioimmunoassay. Our findings indicate that the binding of Factor Xa to "activated" platelets but not to phospholipid micelles results in the protection of the above enzyme from inactivation by the heparin-antithrombin complex. This sequestration of Factor Xa is not affected by the liberation of platelet release proteins or the molecular heterogeneity of the mucopolysaccharide preparations used. The magnitude of enzyme protection is strongly correlated with the extent of prothrombin activation at the time of heparin addition. On this basis, we suggest that high in vivo rates of thrombin generation may lead to the sequestration of Factor Xa on the platelet surface and hence allow this serine protease to resist the action of heparin until the complex is cleared from the circulation.
我们研究了血浆和全血中肝素-抗凝血酶复合物对凝血因子Xa的中和作用。通过测量从凝血酶原裂解的活化片段(F2/F1+2)的浓度来检测这种丝氨酸蛋白酶。F2/F1+2的水平通过灵敏且特异的放射免疫测定法定量。我们的研究结果表明,凝血因子Xa与“活化”血小板结合而非与磷脂微团结合,会使上述酶免受肝素-抗凝血酶复合物的灭活作用。凝血因子Xa的这种隔离不受血小板释放蛋白的释放或所用粘多糖制剂分子异质性的影响。酶保护的程度与添加肝素时凝血酶原激活的程度密切相关。基于此,我们认为体内凝血酶生成的高速率可能导致凝血因子Xa在血小板表面隔离,从而使这种丝氨酸蛋白酶能够抵抗肝素的作用,直到复合物从循环中清除。